Form 4: Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Stock Transactions

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On February 1, 2025, Rhythm Pharmaceuticals CFO Hunter C. Smith vested 4,925 shares of common stock from restricted stock units.
• On February 4, 2025, Smith sold 1,678 shares of common stock at a price of $59.43 per share.
• The sale was executed to cover withholding taxes related to the vesting of the restricted stock units.
• Following these transactions, Smith directly owns 101,186 shares of Rhythm Pharmaceuticals common stock and 9,850 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions, and does not contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It doesn't necessarily reflect a broader trend in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages including restricted stock units are standard practice among publicly traded pharmaceutical companies.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock-based compensation to align executive interests with shareholder value.
• The vesting schedules and terms of these grants are typically detailed in the company's proxy statements.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, Hunter C. Smith, RYTM, Stock Sale, Restricted Stock Units, Vesting, CFO, Beneficial Ownership